ArticleAlzheimer's & dementia (New York, N. Y.)
Bioenergetic data from a creatine monohydrate pilot trial in Alzheimer's disease.
Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05383833 (Creatine to Augment Bioenergetics in Alzheimer's), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Creatine to Augment Bioenergetics in Alzheimer's
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundCreatine monohydrate (CrM) may mitigate bioenergetic failure in Alzheimer's disease (AD) by supporting ATP buffering and modulating mitochondrial function. Building upon our previous findings that CrM is associated with increased brain creatine (Cr) and improved cognition in AD, we investigated our hypothesis that CrM is associated with improved bioenergetic biomarkers in AD.
methodsIn this single-arm pilot featuring participants with AD (
resultsBrain NAA and GSH did not change. In females only, both platelet and lymphocyte mitochondrial respiration increased ( DISCUSSION: These data suggest CrM may augment systemic energy availability in both sexes and mitochondrial capacity in a sex-specific manner in AD. Interpretation of results from this pilot study is limited by lacking a control group, small sample size, and its relatively short timeframe. However, these preliminary findings support further investigation of CrM as a potential bioenergetic intervention in AD with well-designed RCTs, including exploration of potential sex-specific bioenergetic responses to CrM. Trial Registration: ClinicalTrials.gov, NCT05383833, registered on May 20, 2022.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.